Xiflam
Phase 2- Indications
- Diabetic Macular Edema, Diabetic Chronic Kidney Disease, Intermediate Age-related Macular Degeneration
Company intelligence / Profile preview
InflammX Therapeutics, Inc.
Tampa, Florida, United Statesinflammx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
InflammX’s lead candidate Xiflam™ has demonstrated safety in over 1000 patients across multiple Phase 1/2 studies with no significant safety concerns. Preclinical models show efficacy in both structural and functional endpoints for dry AMD and diabetic retinopathy. The drug acts by inhibiting the pathological Cx43 hemichannel to modulate the NLRP3 inflammasome pathway. Current clinical development includes a Phase 2 randomized trial in early-stage DME supported by the DRCR Retina Network of the National Eye Institute and Breakthrough T1D[2][4].
- Therapeutic areas
- OphthalmologyNephrology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Bausch + Lomb – global option agreement for potential acquisition of InflammX Therapeutics[4][7]DRCR Retina Network of the National Eye Institute – supporting current clinical trial[4]Breakthrough T1D – supporting current clinical trial[4]
Beyond the preview
Go deeper on InflammX Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InflammX Therapeutics, Inc..